RBN-2397 NEW
| Price | $132 | $328 | $496 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-07-15 |
Product Details
| Product Name: RBN-2397 | CAS No.: 2381037-82-5 |
| Purity: 99.36% | Supply Ability: 10g |
| Release date: 2025/07/15 |
Product Introduction
Bioactivity
| Name | RBN-2397 |
| Description | RBN-2397 is a potent, selective and orally active accross species NAD+ competitive PARP7 inhibitor with IC50 less than 3 nM. |
| In vitro | Inhibition of PARP7 with RBN-2397 can potently inhibit the growth of cancer cells and restore interferon signaling, effectively releasing the brake cancer uses to hide from the immune system and suppress both innate and adaptive immune mechanisms.RBN-2397 inhibits cells proliferation(IC50 value of 20 nM in NCI-H1373 lung cancer cells), shows a restoration of type I IFN response by an increase in STAT1 phosphorylation as a dose-dependent manner in NCI-H1373 human lung cancer cells,and inhibits cell MARylation in a cell biochemial assay with an EC50 value of 1 nM[2]. |
| In vivo | RBN-2397 oral administration induces tumor-specific adaptive immune memory in CT26 syngeneic model with durable complete responses in CT26 tumor-bearing BALB/c mice.RBN-2397 oral administration causes complete regressions at the dose 100 mg/kg and exerts a dose-dependent effects on tumor growth at dose levels of ≥30 mg/kg.The half-life (t1/2) of RBN-2397 in vivo is 325 mins[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 247 mg/mL (471.89 mM), Sonication is recommended. |
| Keywords | tumor | squamous | solid | RBN-2397 | RBN2397 | RBN 2397 | poly ADP ribose polymerase | PARP-7 | PARP7 | PARP | ovarian | NSCLC | metastatic | lung | Inhibitor | inhibit | cell | carcinoma | advanced |
| Inhibitors Related | 4'-Methoxychalcone | Niraparib tosylate monohyrate | VPC-70063 | 3-Aminobenzamide | XAV-939 | Niraparib | 3-Methoxybenzamide | NU1025 | Olaparib | Benzamide | Picolinamide | OUL35 |
| Related Compound Libraries | DNA Damage & Repair Compound Library | Bioactive Compound Library | Epigenetics Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Aging Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/25KG/CTN |
Shaoxing Anpai Import & Export Co. Ltd
|
2021-07-07 | ||
| $132.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2025-07-15 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY